A standardised clinical monitoring report presenting RQ-PCR BCR-ABL transcripts levels in a CML patient undergoing Tyrosine Kinase inhibitor therapy
Patient prognosis and discussion of potential treatment options for the patient, based on RQ-PCR data obtained and current therapy regimes available and under development for CML patients
The Presentation material and presenter must cover the following
An Overview of CML and TKI therapy in CML treatment (2 slides maximum) (10%)
An explanation of RQ-PCR methodology for CML diagnosis/prognosis and how data can predict patient disease status and response to treatment (1 slide) (10%)
A summary of patient clinical background and current treatment regime (1 slide)
Explanation of intention of the practical, regarding determining patient disease status/prognosis and possible treatment options (1 - slide)
Main results, see guidance below (4 slides maximum) (40%)
Discussion and clinical prognosis slides, see guidance below (3 slides maximum) (40%)
Results slides All results slides must have a suitable fully explanatory title and all figures/data must have bullet-point lists that provide note form information on how to interpret figure/table data and 'take-home messages' of the key results. RQ-PCR data figures must be created using the BioRad CFX manager program
The following results figures and tables must be included
Plasmid extraction data slide: including concentration, copy number calculation used for the creation of dilution series and gel image (individual result and ‘best’ data result)
RNA extraction: concentration and RNA quality data (individual result and ‘best’ data result)
Standard curves for Reference gene (ABL - supplied data) and BCR-ABL (individual data and ‘best' data result). Excel figures + E values
% Normalised copy number for BCR-ABL1 in reference and patient samples (individual data and ‘best' data) and % Normalised copy number (IS-NCN) determination
*You must determine which data are the best data sets and explain why you chose these data as the best data. Slide bullet points (or legends) must explain key take-home messages figures/data shows
Discussion and clinical prognosis slides
These slides should cover 3 sections.
The validity of the results obtained in the practical. Highlight any issues that may have affected the accuracy/precision of individual data results and the best data results
A conclusion summary/discussion of the ’normalised expression levels’ and normalised copy numbers of BCR-ABL1 in reference and patient samples. Discuss what conclusions can you draw from this data, in relation to the ‘success’ of the current TKI therapy regime for the patient.
Discuss treatment options recommended for the patient, based on the ‘best’ RQ-PCR results and the patient's clinical history. Include a discussion of further ‘tests’ that could be carried out to validate your treatment suggestions. All discussion sections must be fully and appropriately referenced.
Sample Solution